Since the 16 Gy + anti-CTLA4 combination acts directly on priming and activating T cells in TDLNs, and subsequently indirectly on tumor infiltration, this is consistent with having more notable differential gene expression in TDLNs compared to tumors. This evidence concerns the gene CTLA4 and neoplasm.